These results follow the trend shown in previous research indicating a relationship between SHP2 and insulin signaling and suggest SHP2 inhibition as a promising therapeutic method for not only cancer treatment, but also treatment of insulin resistance and diabetes. Here, PTPN11 is linked to cancer.